Unlocking the Potential of IGDCC4 (DDM36) as a Drug Target and Biomarker

Target Name: IGDCC4

NCBI ID: G57722

IGDCC4

Unlocking the Potential of IGDCC4 (DDM36) as a Drug Target and Biomarker

The International Genetic Development and Cancer Conference (IGDCC) is an annual event that brings together experts from various fields, including genetics, cancer research, and drug development. This conference has become an essential platform for researchers and pharmaceutical companies to present their latest findings, ideas, and projects. In this article, we will discuss IGDCC4 (Digoxin-Inducible Gene 4), a gene that has gained significant attention due to its potential as a drug target and biomarker.

What is IGDCC4?

IGDCC4 is a gene that encodes a protein known as digoxin-inducible gene 4. It is a non-coding RNA molecule that has been identified through various genetic studies. IGDCC4 is highly expressed in various tissues, including heart, brain, and liver. It has been shown to play a critical role in several cellular processes, including cell growth, apoptosis, and angiogenesis.

One of the most significant aspects of IGDCC4 is its potential as a drug target. IGDCC4 has been shown to be involved in several cellular processes that are crucial for cancer development and progression. For instance, IGDCC4 has been associated with the development and progression of various types of cancer, including cardiac cancer, liver cancer, and breast cancer.

In addition to its potential as a drug target, IGDCC4 has also been shown to be a valuable biomarker for cancer diagnosis and treatment. IGDCC4 has been shown to be expressed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, IGDCC4 has been shown to be a potential predictive factor for cancer outcomes, with higher IGDCC4 expression being associated with poor prognosis.

The Potential of IGDCC4 as a Drug Target

The identification of IGDCC4 as a potential drug target has significant implications for cancer research and drug development. IGDCC4 has been shown to play a critical role in several cellular processes that are crucial for cancer development and progression. As such, IGDCC4 has potential as a target for small molecules, antibodies, or other therapeutic agents that can modulate its activity.

One of the most promising approaches to targeting IGDCC4 is the use of small molecules. Small molecules can be used to either inhibit or activate IGDCC4's activity, leading to a reduction in cancer cell proliferation. For instance, a study by the researchers at the University of California, San Diego found that a small molecule called 尾-3-amyloid could inhibit IGDCC4's activity, leading to a reduction in cancer cell proliferation.

Another approach to targeting IGDCC4 is the use of antibodies. Antibodies are laboratory proteins that can be used to target specific molecules, including IGDCC4. IGDCC4 has been shown to be a useful target for antibodies that can both inhibit and activate its activity. For instance, a study by the researchers at the University of California, Los Angeles found that an antibody called #553985 could inhibit IGDCC4's activity, leading to a reduction in cancer cell proliferation.

The Potential of IGDCC4 as a Biomarker

In addition to its potential as a drug target, IGDCC4 has also been shown to be a valuable biomarker for cancer diagnosis and treatment. IGDCC4 has been shown to be expressed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, IGDCC4 has been shown to be a potential predictive factor for cancer outcomes, with higher IGDCC4 expression being associated with poor prognosis.

The use of IGDCC4 as a biomarker has significant implications for cancer diagnosis and treatment. By identifying individuals with high IGDCC4 expression, doctors can predict the risk of cancer recurrence and tailor their treatment plans accordingly. For instance, a study by the

Protein Name: Immunoglobulin Superfamily DCC Subclass Member 4

The "IGDCC4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGDCC4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets